Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Julie Kephart"'
Autor:
Tian Zhang, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, Katherine Franz, Hannah Berg, Georgia S. Karachaliou, Olga G. James, Lauren Howard, Susan Halabi, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George
Publikováno v:
The Prostate. 82:858-866
In preclinical models of prostate cancer (PC), disulfiram (DSF) reduced tumor growth only when co-administered with copper (Cu), and Cu uptake in tumors is partially regulated by androgen-receptor signaling. However, prior trials of DSF in PC used DS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::389b9340e8a0b2f820500bda19fd92fa
https://doi.org/10.1002/pros.24329
https://doi.org/10.1002/pros.24329
Autor:
Devika Das, Terry Hyslop, Steven R. Patierno, Guru Sonpavde, Bonnie LaCroix, Tian Zhang, Brendon M. Patierno, Julia Rasmussen, Andrew J. Armstrong, A. Oliver Sartor, Patrick Healy, Kouros Owzar, James D. Bearden, Jennifer A. Freedman, Michael Moses Goodman, Kellie Shobe, Matthew I. Milowsky, Mark D. Fleming, Megan Ann McNamara, Michael R. Harrison, Julie Kephart, William R. Berry, Rhonda Wilder, Monika Anand, Carol Winters, Rick A. Kittles, Rhonda L. Bitting, Dadong Zhang, Colleen Riggan, Daniel J. George, Alexander B. Sibley, Elisabeth I. Heath, Susan Halabi
Publikováno v:
Cancer
BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9e89aef748ac8f02d2673256ae775f
https://doi.org/10.1002/cncr.33589
https://doi.org/10.1002/cncr.33589
Autor:
Carolyn Winters, Michael S. Humeniuk, Michael R. Harrison, Russell Z. Szmulewitz, Daniel J. George, Elia Martinez, Susan Halabi, Patrick Healy, Andrew J. Armstrong, Julie Kephart, Kelly Mundy
Publikováno v:
The Prostate. 77:385-395
BACKGROUND Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4238ce5e2558ee7da6365a5d06bbdbdd
https://doi.org/10.1002/pros.23277
https://doi.org/10.1002/pros.23277
Autor:
Hannah Berg, Andrew J. Armstrong, Olga James, Christine Daly, Monika Anand, Elizabeth Bronson, Patrick Healy, Ivan Spasojevic, Julie Kephart, Susan Halabi, Daniel J. George, Michael R. Harrison, Tian Zhang
Publikováno v:
Journal of Clinical Oncology. 38:96-96
96 Background: In preclinical models of prostate cancer (PC), DSF reduced tumor growth when co-administered with copper (Cu). Further, intracellular Cu uptake is partially regulated by androgen-receptor signaling. Given these data, we conducted a pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbe36845494c3df5dc985580fa31dd52
https://doi.org/10.1200/jco.2020.38.6_suppl.96
https://doi.org/10.1200/jco.2020.38.6_suppl.96
Autor:
Allison Martin, Jorge A. Garcia, Moshe Chaim Ornstein, Kunal Desai, Sundhar Ramalingam, Timothy D. Gilligan, Laura S. Wood, Patrick Healy, Emily N. Kinsey, Tian Zhang, Michael R. Harrison, Andrew J. Armstrong, Landon Carter Brown, Daniel J. George, Shilpa Gupta, Kimberly D Allman, Chester Kao, Wei Wei, Julie Kephart, Brian I. Rini
Publikováno v:
Journal of Clinical Oncology. 38:648-648
648 Background: Ipilimumab & nivolumab (I+N) followed by nivolumab maintenance is approved as front-line therapy for intermediate and poor-risk metastatic renal cell carcinoma (mRCC). Bone metastases (BM) are present in up to 30% of mRCC patients (pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50fd63f85aaa9f814ec98dcf120d2868
https://doi.org/10.1200/jco.2020.38.6_suppl.648
https://doi.org/10.1200/jco.2020.38.6_suppl.648
Autor:
Wei Wei, Kimberly D Allman, Andrew J. Armstrong, Allison Martin, Julie Kephart, Landon Carter Brown, Kunal Desai, Tian Zhang, Emily N. Kinsey, Shilpa Gupta, Patrick Healy, Jorge A. Garcia, Brian I. Rini, Sundhar Ramalingam, Laura S. Wood, Michael R. Harrison, Daniel J. George, Chester Kao, Moshe Chaim Ornstein, Timothy D. Gilligan
Publikováno v:
Journal of Clinical Oncology. 38:637-637
637 Background: The combination of ipilimumab & nivolumab (I+N) followed by maintenance nivolumab has improved outcomes in patients (pts) with mRCC. Little is known about the outcomes in mRCC pts with brain metastasis. In this multicenter retrospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc9e015f747a6b0e63ddd74ce12cf08e
https://doi.org/10.1200/jco.2020.38.6_suppl.637
https://doi.org/10.1200/jco.2020.38.6_suppl.637
Autor:
Andrew J. Armstrong, Julie Kephart, Patrick Healy, Daniel J. George, Colleen Soleau, Kelly Mundy, Evan Y. Yu, Tomasz M. Beer, Carolyn Winters, Rhonda L. Bitting, Joshi J. Alumkal, Rachel Slottke, Carey Hobbs, Susan Halabi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 81
Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. Methods This was a multisite singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f7ca99d570d0a5a43f9176af01fbe9
https://pubmed.ncbi.nlm.nih.gov/28629596
https://pubmed.ncbi.nlm.nih.gov/28629596
Autor:
Julie Kephart, Colleen Riggan, Tian Zhang, Andrew J. Armstrong, A. Oliver Sartor, Matthew I. Milowsky, Guru Sonpavde, K. C. Balaji, Daniel J. George, Jennifer A. Freedman, Deborah Watkins Bruner, Mark D. Fleming, Carolyn Winters, Elisabeth I. Heath, Michael R. Harrison, Susan Halabi, Patrick Healy, Megan Ann McNamara, William R. Berry, Rhonda L. Bitting, Monika Anand
Publikováno v:
Journal of Clinical Oncology. 36:LBA5009-LBA5009
LBA5009 Background: Pivotal trials of AAP for patients with mCRPC enrolled few B pts, a population with a higher mortality from prostate cancer. Retrospective data suggests B pts may have higher PSA response rates than W pts treated with AAP for mCRP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84a22a1bf781f1eb257aa313658dba2a
https://doi.org/10.1200/jco.2018.36.18_suppl.lba5009
https://doi.org/10.1200/jco.2018.36.18_suppl.lba5009
Autor:
Jen-Tsan Ashley Chi, Rex C. Bentley, Rosanne G.J. Tiller, Katherine K. Slemmons, Po-Han Chen, Julie Kephart, Corinne M. Linardic, Ashley Hinson, Lisa E.S. Crose
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(21)
Purpose: Rhabdomyosarcoma (RMS) is a soft tissue sarcoma associated with the skeletal muscle lineage. Of the two predominant subtypes, known as embryonal (eRMS) and alveolar (aRMS), aRMS has the poorer prognosis, with a five-year survival rate of Exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d88d933a628da7859d3dabcf3c9ea3f
https://pubmed.ncbi.nlm.nih.gov/26071485
https://pubmed.ncbi.nlm.nih.gov/26071485
Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
Autor:
Julien Fitamant, Rex C. Bentley, Nabeel Bardeesy, Jen Tsan Ashley Chi, Candy Chen, Corinne M. Linardic, Rene L. Galindo, Kathleen A. Galindo, Julie Kephart, Lisa E.S. Crose
Publikováno v:
The Journal of clinical investigation. 124(1)
Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skeletal muscle characterized by expression of the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncogene. Despite its discovery nearly two decades ago, the mechanisms by which P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6217830997962a8ce6ff241e34235a06
https://pubmed.ncbi.nlm.nih.gov/24334454
https://pubmed.ncbi.nlm.nih.gov/24334454